회사 개요
Bio Green Med Solution, Inc. (BGMS) is primarily engaged in the distribution, trading, and installation of protective and fire safety materials, equipment, and systems, alongside research and development activities in the pharmaceutical sector. The company operates within the Healthcare sector, specifically classified under the Biotechnology industry, which typically involves high levels of innovation and regulatory oversight. As of the latest reporting period, the firm maintains a market capitalization of $5.57M and reported annual revenue of $747,000, while the specific employee count is not disclosed in the available financial data. These valuation and revenue figures indicate that BGMS functions as a micro-cap entity with a very small operational scale, reflecting its status as a smaller player in the broader healthcare and biotechnology landscape where capital efficiency is critical for survival.
재무 건전성
The company reported a trailing twelve-month revenue of $747,000, yet generated a significant net income loss of $-14,092,000, creating a substantial gap that reveals an aggressive cost structure or significant one-time charges eroding profitability. The EBITDA for the period stood at $-8,422,000, further highlighting the operational challenges the firm faces in generating cash from its core business activities. Free cash flow was reported at $-10,077,875, indicating that the company is burning through its cash reserves rapidly and currently lacks the financial flexibility to fund operations without external capital injections. The gross margin stands at -90.1%, operating margin at -162.5%, and profit margin at 0.0%, suggesting that the cost of goods sold exceeds revenue and that the company is operating at a severe structural loss on its primary products. Despite these losses, the balance sheet shows a cash position of $3.50M against negligible debt of $2,000, resulting in a debt-to-equity ratio of 0.03, which points to a highly conservative leverage profile with minimal interest obligations. The current ratio is 4.70, indicating that the company holds ample current assets relative to its current liabilities and possesses strong short-term liquidity to cover immediate obligations. However, the return on equity is -128.4% and return on assets is -85.8%, revealing that management has not been effective at generating positive returns on the shareholders' capital or the company's asset base during this reporting period.
밸류에이션 평가
The trailing P/E ratio and forward P/E ratio are both listed as N/A due to the lack of positive earnings, meaning traditional earnings-based valuation multiples cannot be calculated to assess the trajectory of expected earnings. The price-to-book ratio is 0.80, which indicates that the market is valuing the company at a discount to its net asset value, implying no market premium over the book value of its equity. The price-to-sales ratio is 7.46, while the EV/EBITDA stands at -0.25, suggesting that investors are pricing the stock based on revenue multiples rather than earnings power, often seen in companies with negative profitability but potential future growth. The 52-week high is $100.80 and the 52-week low is $0.73, meaning the current share price sits significantly below the 52-week high, reflecting a period of substantial volatility and correction from previous price levels. The beta value is -0.53, which is an anomalous negative figure indicating that the stock price tends to move in the opposite direction of the broader market, offering a unique volatility profile distinct from standard equities.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of earnings growth speed relative to revenue growth within this specific reporting window. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning the firm retains all its earnings rather than distributing them to shareholders. Consequently, the company reinvests its limited financial resources back into its research and development operations or working capital rather than paying dividends to investors. The overall growth and income profile for Bio Green Med Solution, Inc. is characterized by negative earnings, a lack of dividend income, and a reliance on retained cash reserves to fund operations in the absence of positive organic growth metrics.